JP2015536301A5 - - Google Patents

Download PDF

Info

Publication number
JP2015536301A5
JP2015536301A5 JP2015535891A JP2015535891A JP2015536301A5 JP 2015536301 A5 JP2015536301 A5 JP 2015536301A5 JP 2015535891 A JP2015535891 A JP 2015535891A JP 2015535891 A JP2015535891 A JP 2015535891A JP 2015536301 A5 JP2015536301 A5 JP 2015536301A5
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
composition according
urine
measuring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015535891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015536301A (ja
JP6272880B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/063884 external-priority patent/WO2014058881A1/en
Publication of JP2015536301A publication Critical patent/JP2015536301A/ja
Publication of JP2015536301A5 publication Critical patent/JP2015536301A5/ja
Application granted granted Critical
Publication of JP6272880B2 publication Critical patent/JP6272880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015535891A 2012-10-09 2013-10-08 アルポート症候群の処置方法 Active JP6272880B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261711514P 2012-10-09 2012-10-09
US61/711,514 2012-10-09
US201361779137P 2013-03-13 2013-03-13
US61/779,137 2013-03-13
PCT/US2013/063884 WO2014058881A1 (en) 2012-10-09 2013-10-08 Methods for treatment of alport syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017253345A Division JP2018080190A (ja) 2012-10-09 2017-12-28 アルポート症候群の処置方法

Publications (3)

Publication Number Publication Date
JP2015536301A JP2015536301A (ja) 2015-12-21
JP2015536301A5 true JP2015536301A5 (https=) 2016-12-01
JP6272880B2 JP6272880B2 (ja) 2018-01-31

Family

ID=49382663

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015535891A Active JP6272880B2 (ja) 2012-10-09 2013-10-08 アルポート症候群の処置方法
JP2017253345A Pending JP2018080190A (ja) 2012-10-09 2017-12-28 アルポート症候群の処置方法
JP2019189071A Pending JP2020073479A (ja) 2012-10-09 2019-10-16 アルポート症候群の処置方法
JP2022083586A Pending JP2022110140A (ja) 2012-10-09 2022-05-23 アルポート症候群の処置方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017253345A Pending JP2018080190A (ja) 2012-10-09 2017-12-28 アルポート症候群の処置方法
JP2019189071A Pending JP2020073479A (ja) 2012-10-09 2019-10-16 アルポート症候群の処置方法
JP2022083586A Pending JP2022110140A (ja) 2012-10-09 2022-05-23 アルポート症候群の処置方法

Country Status (34)

Country Link
US (8) US9012423B2 (https=)
EP (2) EP3620522B1 (https=)
JP (4) JP6272880B2 (https=)
KR (4) KR20220005634A (https=)
CN (1) CN104718295B (https=)
AR (1) AR092940A1 (https=)
AU (3) AU2013329427B2 (https=)
BR (1) BR112015007709B1 (https=)
CA (1) CA2885605A1 (https=)
CL (1) CL2015000873A1 (https=)
CR (1) CR20150236A (https=)
CY (1) CY1122479T1 (https=)
DK (1) DK2906698T3 (https=)
EA (1) EA201590711A1 (https=)
ES (2) ES2960488T3 (https=)
HR (1) HRP20191948T1 (https=)
HU (1) HUE045858T2 (https=)
IL (2) IL237768B (https=)
LT (1) LT2906698T (https=)
MX (1) MX356340B (https=)
MY (1) MY183921A (https=)
NZ (1) NZ630596A (https=)
PH (1) PH12015500781B1 (https=)
PL (1) PL2906698T3 (https=)
PT (1) PT2906698T (https=)
RS (1) RS60014B1 (https=)
SG (1) SG11201502748RA (https=)
SI (1) SI2906698T1 (https=)
TN (1) TN2015000099A1 (https=)
TW (1) TWI641388B (https=)
UA (1) UA116639C2 (https=)
UY (1) UY35069A (https=)
WO (1) WO2014058881A1 (https=)
ZA (1) ZA201502087B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
EP3211082B1 (en) 2011-04-25 2021-02-17 Sanofi Microrna compounds and methods for modulating mir-21 activity
PE20142404A1 (es) 2012-04-25 2015-02-02 Regulus Therapeutics Inc Compuestos de microarn y metodos de modulacion de la actividad de mir-21
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
US9994846B2 (en) 2013-10-25 2018-06-12 Regulus Therapeutics Inc. MicroRNA compounds and methods for modulating miR-21 activity
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CA2955481A1 (en) * 2014-07-25 2016-01-28 Goldfinch Biopharma, Inc. Collagen iv replacement
WO2016029027A2 (en) * 2014-08-21 2016-02-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of disease
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
EP3359685B1 (en) 2015-10-09 2026-01-28 University Of Southampton Modulation of gene expression for deregulated protein expression
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
EP3933041B1 (en) 2015-12-14 2024-01-31 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant retardation
KR102486434B1 (ko) 2016-11-08 2023-01-09 리아타 파마슈티컬즈 홀딩스, 엘엘씨 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
CN110199023A (zh) * 2016-12-28 2019-09-03 第一三共株式会社 阿尔波特氏综合症治疗药
US20210100828A1 (en) * 2017-05-04 2021-04-08 Sanofi Methods for Treatment of Alport Syndrome
KR20200026874A (ko) 2017-06-06 2020-03-11 지머젠 인코포레이티드 대장균 개량을 위한 htp 게놈 공학 플랫폼
KR20200026878A (ko) 2017-06-06 2020-03-11 지머젠 인코포레이티드 균류 균주를 개량하기 위한 htp 게놈 공학 플랫폼
SG11202001590RA (en) 2017-08-25 2020-03-30 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
GB2610100B (en) * 2017-10-23 2023-08-16 Stoke Therapeutics Inc Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases
US12060558B2 (en) 2018-05-04 2024-08-13 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
EP3874037A4 (en) 2018-10-31 2021-12-15 Zymergen, Inc. DETERMINIST MULTIPLEXED SET OF DNA LIBRARIES
KR20210134003A (ko) 2019-02-27 2021-11-08 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 안티센스 올리고머
US11053515B2 (en) 2019-03-08 2021-07-06 Zymergen Inc. Pooled genome editing in microbes
CN113728106A (zh) 2019-03-08 2021-11-30 齐默尔根公司 微生物中的迭代基因组编辑
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
IL296394A (en) 2020-03-20 2022-11-01 Keros Therapeutics Inc Type ii activin receptor chimeras and methods of using them
BR112022022889A2 (pt) 2020-05-11 2023-04-04 Stoke Therapeutics Inc Oligômeros antissentido de opa1 para tratamento de condições e doenças
EP4522162A1 (en) * 2022-05-09 2025-03-19 Calliditas Therapeutics Suisse SA Nox inhibitors for use in the treatment of alport syndrome
WO2024238950A1 (en) * 2023-05-18 2024-11-21 Keros Therapeutics, Inc. Methods of using activin receptor type ii variants
WO2025110217A1 (ja) * 2023-11-22 2025-05-30 国立大学法人東海国立大学機構 嚢胞性腎疾患の予防及び／又は治療剤

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ508317A (en) * 1998-05-22 2004-01-30 Boys Town Nat Res Hospital Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease
HK1038886B (zh) * 1998-05-22 2005-09-23 博伊斯镇国家研究医院 α1β1整合蛋白受体抑制剂和TGF-β1抑制剂制备用於治疗肾病的药物组合物的用途
US20060008817A1 (en) 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
EP2390331B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
US7585501B2 (en) * 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US7585550B2 (en) 2004-02-02 2009-09-08 College Of William And Mary Process for modifying polymeric surfaces using deep UV irradiation
EP2290071B1 (en) 2004-05-28 2014-12-31 Asuragen, Inc. Methods and compositions involving microRNA
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
US20080187508A1 (en) * 2004-09-08 2008-08-07 Boys Town National Research Hospital Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
WO2006069584A2 (en) 2004-12-29 2006-07-06 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
WO2007027894A2 (en) 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Antisense compounds having enhanced anti-microrna activity
EP1984499B1 (en) 2006-01-27 2015-05-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
EP2666859B1 (en) 2006-04-03 2019-01-02 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
CA2648132C (en) 2006-04-03 2019-05-28 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP3192788A1 (en) 2006-10-03 2017-07-19 Arbutus Biopharma Corporation Lipid containing formulations
EP2489742A1 (de) 2006-10-09 2012-08-22 Julius-Maximilians-Universität Würzburg MicroRNA (MIRNA) zur Diagnose und Therapie von Herzerkrankungen
WO2008073920A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2008086807A2 (en) 2007-01-19 2008-07-24 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
WO2008151631A2 (en) 2007-06-15 2008-12-18 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
CA2691691C (en) * 2007-06-20 2013-09-24 Seth J. Baum Compositions and methods of treating chronic kidney disease
EP2623599B1 (en) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
EP2217248B1 (en) 2007-10-29 2016-11-30 Regulus Therapeutics Inc. Targeting micrornas for the treatment of liver cancer
US20110257244A1 (en) 2008-01-18 2011-10-20 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
NZ587178A (en) 2008-02-08 2011-11-25 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010099161A1 (en) 2009-02-26 2010-09-02 The Ohio State University Research Foundation Micrornas in never-smokers and related materials and methods
CA2765129A1 (en) 2009-06-08 2010-12-16 Miragen Therapeutics Chemical modification motifs for mirna inhibitors and mimetics
WO2011126842A2 (en) 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
EP3211082B1 (en) 2011-04-25 2021-02-17 Sanofi Microrna compounds and methods for modulating mir-21 activity
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
PE20142404A1 (es) 2012-04-25 2015-02-02 Regulus Therapeutics Inc Compuestos de microarn y metodos de modulacion de la actividad de mir-21
US9388408B2 (en) 2012-06-21 2016-07-12 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
CN104955950B (zh) 2012-09-26 2019-04-26 米尔克斯治疗学公司 具有改善的脱靶特征谱的寡核苷酸
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Similar Documents

Publication Publication Date Title
JP2015536301A5 (https=)
JP2022110140A (ja) アルポート症候群の処置方法
JP2018528945A5 (https=)
HRP20210616T1 (hr) Spojevi mikrornk i postupci za moduliranje aktivnosti mir-21
JP2014518619A5 (https=)
JP2018530325A (ja) アンジオテンシノーゲンの発現を調節するための化合物及び方法
JP2015519891A5 (https=)
RU2018108206A (ru) Способы лечения поликистозной болезни почек
ES2988845T3 (es) Procedimientos predictivos y diagnósticos para cáncer de próstata
Valdivia et al. Plasmapheresis for the prophylaxis and treatment of recurrent focal segmental glomerulosclerosis following renal transplant
JP2019536803A5 (https=)
Roberts et al. Adenosine receptor expression in the development of renal fibrosis following ischemic injury
KR20190093207A (ko) 다낭성 신장 질환의 치료 방법
JP2020518633A5 (https=)
CN102716123A (zh) 一种用于治疗IgA肾病复方制剂
CA3062316A1 (en) Methods for treatment of alport syndrome
EP4453210A1 (en) Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors
JP2008540448A (ja) 糖尿病性腎症の治療において、スロデキシド及び血圧低下薬を用いた併用療法
Tan et al. Protective effects of FR167653 on chronic allograft nephropathy by inhibiting p38 MAPK in rats
WO2024102913A1 (en) Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (slc5a2) inhibitors
WO2007059435A9 (en) Compositions and methods for enhancing cognitive function